Interspecies recombination contributes minimally to fluoroquinolone resistance in Streptococcus pneumoniae

Antimicrobial Agents and Chemotherapy

Volumn 45, Issue 9, 2001, Pages 2631-2634

  Bast, D J ^a   De Azavedo, J C S ^a   Tam, T Y ^a   Kilburn, L ^a   Duncan, C ^a   Mandell, L A ^a   Davidson, R J ^a   Low, D E ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); QUINOLINE DERIVED ANTIINFECTIVE AGENT;

AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ARTICLE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SPECIES DIFFERENCE; STREPTOCOCCUS PNEUMONIAE;

AMINO ACID SEQUENCE; ANTI-INFECTIVE AGENTS; BACTERIAL PROTEINS; DNA GYRASE; DNA TOPOISOMERASE IV; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; DRUG RESISTANCE, MICROBIAL; FLUOROQUINOLONES; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; RECOMBINATION, GENETIC; SEQUENCE HOMOLOGY, AMINO ACID; STREPTOCOCCUS PNEUMONIAE;

EID: 0034869512     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.45.9.2631-2634.2001     Document Type: Article

References (27)

1. Fluoroquinolone resistance among recent clinical isolates of Streptococcus pneumoniae
2. Quinolone resistance: Older concepts and newer developments
3. Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: Contributions of type II topoisomerase mutations and efflux to levels of resistance
4. Heterospecific transformation of pneumococcus and streptococcus. IV. Variations in hybrid DNA produced by recombination
5. Genetic and transcriptional organization of the region encoding the beta subunit of Bacillus subtilis RNA polymerase
6. Prevalence of a putative efflux mechanism among fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
7. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada
8. In vitro activities of fluoroquinolones against antibiotic-resistant blood culture isolates of viridans group streptococci from across Canada
9. Origin and molecular epidemiology of penicillin-binding-protein-mediated resistance to beta-lactam antibiotics
10. Horizontal transfer of parC and gyrA in fluoroquinolone-resistant clinical isolates of Streptococcus pneumoniae
11. Drug efflux and parC mutations are involved in fluoroquinolone resistance in viridans group streptococci
12. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci
13. Fluoroquinolone resistance associated with target mutations and active efflux in oropharyngeal colonizing isolates of viridans group streptococci
14. Emergence of fluoroquinolone resistance among multiple resistant strains of Streptococcus pneumoniae in Hong Kong
15. In vitro exchange of fluoroquinolone resistance determinants between Streptococcus pneumoniae and viridans streptococci and genomic organization of the parE-parC region in S. mitis
16. Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from worldwide surveillance studies during the 1997-1998 respiratory season
17. Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci
18. Deoxyribonucleic acid gyrase-deoxyribonucleic acid complex containing 140 base pairs of deoxyribonucleic acid and an alpha 2 beta 2 protein core
19. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype
20. In vitro selection of resistance to clinafloxacin, ciprofloxacin, and trovafloxacin in Streptococcus pneumoniae
21. TREEVIEW: An application to display phylogenetic trees on personal computers
22. Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae
23. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: Selective targeting of gyrase or topoisomerase IV by quinolones
24. Escherichia coli topoisomerase IV. Purification, characterization, subunit structure, and subunit interactions
25. Characterization of a mutation in the parE gene that confers fluoroquinolone resistance in Streptococcus pneumoniae
26. Intracellular targets of moxifloxacin: A comparison with other fluoroquinolones
27. Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro